Meeting
2011 ASCO Annual Meeting
The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis.
Authors
J. Chiu
Department of Medicine, Hong Kong, China
J. Chiu , Y. F. Tang , T. J. Yao , A. Wong , H. Wong , R. C. Leung , P. Chan , T. T. Cheung , R. T. P. Poon , S. T. Fan , C. C. Yau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4083)
Abstract #
4083
Poster Bd #
33A
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
A phase II study of palbociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma.
First Author: Susan Joy Littman
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
First Author: Kazufumi Kobayashi
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin
Poster
2018 Gastrointestinal Cancers Symposium
Nivolumab in advanced hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis: Safety and clinical outcomes in a retrospective case series.
First Author: Swetha Kambhampati